Factor V Leiden, Prothrombin and MTHFR Mutation in Patients with Preeclampsia, Intrauterine Growth Restriction and Placental Abruption

Vesna Livrinova1, Marija Hadzi Lega1, Anita Hristova Dimcheva2, Igor Samardziski1, Rozalinda Isjanovska3

1University Clinic for Obstetrics and Gynecology, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 2Institute for Transfusion Medicine, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 3Institute for Epidemiology and Medical Biostatistics, Faculty of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

Abstract

BACKGROUND: Factor V Leiden, Prothrombin and MTHFR gene mutation, could have an influence in pregnancy with adverse outcome Preeclampsia, IUGR and Placental abruption.

AIM: The aim of this study is to investigate the presence of above mentioned inherited thrombophilias and its statistical significance, distribution among the complicated and normal pregnancy, and relative risk for carrier of mutation to develop preeclampsia, IUGR and placental abruption.

MATERIAL AND METHODS: Prospective cohort study is implemented at University Clinic for Obstetric and Gynecology in Skopje, Republic of Macedonia. The study included 109 delivered patients: 40 with preeclampsia, 22 with IUGR, 17 with placental abruption and 30 as control group with normal pregnancy. The amount of 3 ml venous blood has been used for detection of these point mutations using ThromboStrip -Opegen, QIAGEN kit manufactured for thrombotic risk.

RESULTS: The highest frequency was found: in the group with preeclampsia 35% were Factor V Leiden heterozygous, IUGR -MTHFR heterozygous 45%, Placental abruption- 52.9% MTHFR heterozygous, and in the control group without thrombophilia 56.7%. There were combined thrombophilia in 3 patients. There aren’t statistical significance in presence of thrombophilia among groups (p > 0.05). Statistical significance (p < 0.05) was found between carriers of MTHFR homozygous in preeclampsia and group with placental abruption and control group. Relative risk in IUGR group for MTHFR homozygous was 5.54 (1.37<RR<22.4). Relative risk in placental abruption for Factor V Leiden heterozygous was 4.50 (0.47<RR<42.75).

CONCLUSION: The presence of mutation MTHFR homozygous could increase the risk for development of IUGR and mutation of Factor V Leiden for placental abruption. Further investigations with more patients are warranted.

Introduction

Adequate fetomaternal circulating system is essential for normal development and function of placenta. It is obtained with mechanism which prevents coagulation of the maternal blood around choriionic villas and fetal blood in them [1]. Normal pathway in coagulation cascade includes balance between procoagulants, anticoagulant and fibrinolytic components in blood. Depend of the type of inherited thrombophilia, there is impaired neutralization of thrombin or failure to control generation of thrombin [2, 3]. This will cause malfunction of natural anticoagulants that maintain the fluidity of the blood. In normal circumstances, activated Factor V has procoagulant and anticoagulant activity in the same time. Activated Protein C inactivates factors Va and
VIIa and limiting the generation of thrombin. When gene for synthesis of factor V is mutated, there is Arg506Gln substitution, and one of the three cleavage sites for activated Protein C is inactive, without proteolysis inactivation of factor V.

On the other side factor V and factor VIII have augmentation effect for conversion of prothrombin to thrombin. Final effect is increased generation of thrombin and in vitro resistance to activated protein C to prolong activated partial-thromboplastine time [4, 5]. Mutation G20210A in 3' untranslated region of Prothrombin gene is associated with an increase level of plasma Prothrombin and consecutive excessive thrombin generation. In homozygous, hyperhomocisteinemia is as a result of C677T mutation in the gene for synthesis of MTHFR, lead to synthesis of thermo labile molecule of protein MTHFR with decrease enzyme activity in conversion of homocistein to metionin.

The pathogenesis for thrombophilia due to this mutation is still unknown [6]. The frequency of FV Leiden in white healthy individuals is 1%-15% in heterozygous and less than 1% in homozygous [6, 7]. In Macedonia the frequency is 5.5% in general population, with difference between Macedonian population 6.9% and 2.9% in Albanian population, without statistical significant difference between the males and females [8]. Prothrombin gene mutation is 2.7%-7% and for MTHFR 5%-15% homozigous manner, and in 30-50% in heterозygous manner [9, 10]. These inherited thrombophilia substantially increased the risk for deep venous thrombosis and pulmonary thrombembolism during pregnancy and puerperium. Also they increase the risk for fetal loss after 20 weeks of gestation, especially after 28 weeks. In one more general study, it was found presence of 52% in pregnancy with preeclampsia, IUGR, placental abruption and stillbirth and they were heterozygous for Factor V Leiden, prothrombin gen mutation or homozygous for MTHFR gene mutation, as compared with 17% total of controls [11-13].

The aim of this study is to investigate the presence of above mentioned inherited thrombophilias and its statistical significance, distribution among the complicated and normal pregnancy, and relative risk for carrier of mutation to develop preeclampsia, IUGR and placental abruption.

Material and Methods

This study was submitted and approved by the Ethical Review Committee of the Medical University in Skopje and is in adherence to the laws and regulations of the country in which the research was conducted. Written consent with patient permission was obtained from each patient.

This prospective cohort study was conducted at the University Clinic for Obstetric and Gynecology in Skopje, included 109 successively admitted and delivered patients during period of one year from March 2014 to March 2015. All delivered neonates were without sign of congenital infection, malformation and chromosomopathies.

The patients were distributed in four groups. The first group was consist from 40 patients with preeclampsia (PE), second group from 22 patients with intrauterine growth restriction (IUGR), third group from 17 patients with placental abruption (AP) and 30 patients as a control group of normal pregnancies and term spontaneous delivered healthy neonates. Inclusion criteria for PE was presence of proteinuria at least 0.5 g/L/24 hours, increase in systolic pressure for minimum 30 mmHg, and diastolic pressure 15 mmHg, measured two times apart for six hours, compared with blood pressure before pregnancy. Exclusion criteria were underlying pre existential morbidity: chronic hypertension, diabetes, renal disease, autoimmune and metabolic disease (NICE guidelines). Inclusion criteria for IUGR were birth weight less than 5th percentile for gestational age and sex and exclusion criteria were presence of congenital infection, anomalies and chromosomopathies and mother who took medication, alcohol and with toxicomania. The placental abruption was clinically and/or histopathologically proven and exclusion criteria were rupture of membrane, uterine fibroid or other operation of uterus [13]. The differences between the numbers of participating patient are due to different frequency of each clinical entity. PE occurred in 8%-10%, IUGR 2%-3% and placental abruption 0.5%. During that period there were 5600 delivered patients in our clinic.

Methods

After delivery, 3 ml venous blood was taken from each patient with vacutainer in epruvete with anticoagulant EDTA, and send to laboratory at Institute for Transfusion Medicine. For detection of mutations the laboratory used test: ThromboStrip-Opeogen, from QIAGEN (molecular and immune diagnostic).This is a test for point gene mutations associated with venous thrombotic risk. ThromboStrip can detect three point mutations: G1691A for factor V, G20210A for prothrombin gene and C677T mutation for MTHFR gene. The procedure consists of these successive steps: DNA extraction, PCR amplification, hybridization, strip developing and detection. DNA extraction is manually from leucocytes from venous blood (spin protocol) with saline precipitation. After that, checking is preformed on 3% agarose gel for the presence fragments of free DNA. PCR was conducted on Ependorf (amplification of DNA fragments). Test membrane carried covalently attached DNA probes
which specifically could recognize every gene amplified sequence. There are two probe carriers for each gene – one normal and one mutated. The next phase is hybridization detection on machine AutoLipa 48, where probe carrier is specific attached for DNA fragments. The blue precipitation is shown at the place where hybridisation is. There are three possible results: no mutation, homozygous or heterozygous and it compares with control probe ThromboStrip on 3% agarous gel. Depends of appearance of blue band: one or two bands on test probe, the mutation are detected (Fig. 1). Sensitivity and specificity are limited only from the amount of DNA specimens (if there are 100 DNA fragments, compared with other methods, results concordant is 100%).

Figure 1: Example of genotyping using ThromboStrip quality control

Statistical method

SPSS V.20 was used for numeric and attributive parameterats. Standard descriptive and analytical bivariate and multivariant methods were used. Statistical significans among attributive parameters was determined wit Chi-square test, and numerical parameters with Student’s t test.

Results

A total of 109 patients were analyzed in this study. The patients were distributed in four groups - 40 patients with preeclampsia (PE), II- 22 patients with intrauterine growth restriction (IUGR), III- 17 patients with placental abruption (AP) and IV-30 patients as a control group of normal pregnancies and term spontaneous delivered healthy neonates.

Demographic data are presented: patient age-years (see Table 1) and ethnicity (see Table 2).

Table 1: Age distribution

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean</th>
<th>No</th>
<th>SD</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>29.4</td>
<td>40</td>
<td>6.9</td>
<td>18.0</td>
<td>43.0</td>
</tr>
<tr>
<td>II</td>
<td>31.3</td>
<td>22</td>
<td>5.9</td>
<td>21.0</td>
<td>42.0</td>
</tr>
<tr>
<td>III</td>
<td>31.5</td>
<td>17</td>
<td>5.7</td>
<td>20.0</td>
<td>42.0</td>
</tr>
<tr>
<td>IV</td>
<td>30.1</td>
<td>30</td>
<td>4.2</td>
<td>22.0</td>
<td>41.0</td>
</tr>
<tr>
<td>Total</td>
<td>30.3</td>
<td>109</td>
<td>5.8</td>
<td>18.0</td>
<td>43.0</td>
</tr>
</tbody>
</table>

The differences between mean values in patient age in four groups aren’t statistical significant (F=0.730792, p=0.54).

The percent of Albanian and Gipsy population in the group with PE is above of their presence in national structure of population in Macedonia. In control group - 63.3% is Macedonian, Albanians - 20.0%, Gipsy - 6.7% and Bosnians - 10.0%. This distribution is similar with national structure of population in Macedonia.

Distribution of patient’s combination of clinical entities and presence of thrombophilia are presented in Table 3 and Figure 2.

Table 3: Distribution of patient’s combination of clinical entities and presence of thrombophilia

<table>
<thead>
<tr>
<th>Thrombophilia type</th>
<th>III</th>
<th>III-PE</th>
<th>III-PE</th>
<th>III-PE</th>
<th>III-PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>8</td>
<td>20.0</td>
<td>5</td>
<td>22.7</td>
<td>6</td>
</tr>
<tr>
<td>MTHFR heterozygous</td>
<td>12</td>
<td>30.0</td>
<td>10</td>
<td>45.5</td>
<td>9</td>
</tr>
<tr>
<td>MTHFR homozigous</td>
<td>14</td>
<td>35.0</td>
<td>7</td>
<td>31.8</td>
<td>1</td>
</tr>
<tr>
<td>Prothrombin/leiden</td>
<td>4</td>
<td>10.0</td>
<td>1</td>
<td>4.5</td>
<td>1</td>
</tr>
<tr>
<td>Factor V leiden heterozygous</td>
<td>2</td>
<td>5.0</td>
<td>1</td>
<td>4.5</td>
<td>2</td>
</tr>
</tbody>
</table>

In the group with preeclampsia 35% of patient were MTHFR homozygous, 30% MTHFR heterozygous, Prothrombin heterozygous 10%, FV Leiden 5% heterozygous and without thrombophilia 20%.

In the group with IUGR, 31.8% of patient were MTHFR homozygous, 45.5% MTHFR heterozygous, Prothrombin heterozygous and FV Leiden heterozygous 4.5% (coinheritance) and without thrombophilia 22.7%.

In the group with placental abruption, 5.9% of patient were MTHFR homozygous and prothrombin heterozigous (coinheritance), 52.9% MTHFR heterozygous, FV Leiden heterozygous 11.8% and without thrombophilia 35.3%.

In control group (healthy individuals) 6.7% of patient were MTHFR homozygous, 33.3% MTHFR heterozygous, FV Leiden 3.3% heterozygous and without thrombophilia 56.7%. Differences in frequencies present thrombophilia among four groups are without statistical significance for p >0.05.

There was coinherence in two patients in group with IUGR: one with MTHFR homozygous, Prothrombin heterozygous and FV Leiden heterozygous. Another patient from the same group has coinherence of MTHFR and protrombin heterozygous.
The third patient with coinherence - MTHFR and FV Leiden heterozygous was in the group with placental abruption.

Statistical significance for p<0.05 was found in MTHFR homozygous between group with preeclampsia and placental abruption and control group. Statistical significance for p<0.05 was found in absence of thrombophilia between control group and the group with placental abruption and preeclampsia.

RR in PE group for MTHFR heterozygous, MTHFR homozygous and FV Leiden heterozygous was 1.7, 2.73 and 3.06 respectively. RR in IUGR group for MTHFR heterozygous, MTHFR homozygous and FV Leiden heterozygous was 1.8, 5.54 and 2.2 respectively. RR in group with placental abruption for MTHFR heterozygous, MTHFR homozygous and FV Leiden heterozygous was 1.62, 1.36 and 4.5 respectively.

Table 4: Multiple regression analysis

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>B</th>
<th>t (test)</th>
<th>p (level)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.66399</td>
<td>-0.638054</td>
<td>0.525</td>
</tr>
<tr>
<td>Poor obstetric background</td>
<td>-0.404180</td>
<td>-0.416275</td>
<td>0.678</td>
</tr>
<tr>
<td>Positive familial anamnesis</td>
<td>0.272288</td>
<td>0.862150</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Discussion

The impact of inherited thrombophilia in pregnancy is investigated from many authors. Broad spectre of results could be found in literature. Review articles clearly shown the reasons for that finding. The most of them include patients with eclampsia, HELLP syndrome, severe PE, IUGR and placental abruption who were delivered in tertiary care hospitals.

Comparing the results from this study, it could be concluded that in healthy individuals the most frequent mutation is for MTHFR heterozygous, which is similar with the studies from other authors [17] but without thrombophilia were 56.7%, compared with the study of Kumferminc -80%. It was found no statistical significant difference between ethnical origin and thrombophilia in population in Macedonia [8].

Factor V Leiden mutation increased the risk for Preeclampsia has RR form 2.2-6.1 [6, 13-15] compared with RR-3.06 in this study. The most of the studies included patients with PE before 34 gw [16].

The relative risk for carriers of Factor V Leiden mutation was 4.5 in the group with placental abruption, but without statistical significance for other mutations.

Statistical significance for p<0.05 was found in MTHFR homozygous between group with preeclampsia and placental abruption and control group.

Statistical significance for p<0.05 was found in absence of thrombophilia between control group and the group with placental abruption and preeclampsia.

http://www.mjms.mk/
http://www.id-press.eu/mjms/
The relative risks for IUGR for mutation: FV Leiden and Prothrombin are 2.58 and 2.03, p>0.05 [18, 22].

Only consistent result was found between carrier of FV Leiden homozygous and combined gene mutations and deep venous thrombosis in pregnancy and puerperium, where the risk increase to 40 folds [19-21].

In patients with placental abruption, was found RR of 3.9-5.0 for Factor V Leiden mutation [12, 22, 24].

These differences in the results probably are due to different inclusion criteria, the number of patients and selection bias and also because of ethnical background of some thrombophilia [23].

In conclusion, thrombophilia still remain field for further investigations, because a lot of studies shown that clinical expression in patients with thrombophilia are an interrelation between gene-age-environmental circumstances. It is important because the doctor should be offered screening for the patients with risks to develop complications in pregnancy [25].

References